Radiographic progression-free survival in the ACIS trial for prostate cancer

Affiliations

¹ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, 49100, Israel.
³ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, 49100, Israel. Electronic address: tomermrsn@gmail.com.

Comment

Shai Gilboa et al. Lancet Oncol. 2022 Jan.

. 2022 Jan;23(1):e3.

doi: 10.1016/S1470-2045(21)00710-5.

¹ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, 49100, Israel.
³ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, 49100, Israel. Electronic address: tomermrsn@gmail.com.

No abstract available

Conflict of interest statement

We declare no competing interests.

Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply.
Saad F, De Porre P, Brookman-May S, Li J, McCarthy SA, Rathkopf DE. Saad F, et al. Lancet Oncol. 2022 Jan;23(1):e5-e6. doi: 10.1016/S1470-2045(21)00723-3. Lancet Oncol. 2022. PMID: 34973233 No abstract available.

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB Jr, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE; ACIS Investigators. Saad F, et al. Lancet Oncol. 2021 Nov;22(11):1541-1559. doi: 10.1016/S1470-2045(21)00402-2. Epub 2021 Sep 30. Lancet Oncol. 2021. PMID: 34600602 Free PMC article. Clinical Trial.